Compare
Cardiff Lexington Corp vs Airsculpt Technologies, Inc. vs LifeMD, Inc.
| Latest fiscal year | Cardiff Lexington Corp CDIX | Airsculpt Technologies, Inc. AIRS | LifeMD, Inc. LFMD |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.54M | $151.82M | $194.06M |
| Revenue growth (YoY) | +39.5% | -15.8% | +25.3% |
| Gross margin | 62.5% | n/a | 85.7% |
| Operating margin | 9.5% | -7.6% | -4.0% |
| Net margin | -47.7% | -7.7% | 7.4% |
| Net income | -$5.51M | -$11.67M | $14.35M |
| EPS (Diluted) | n/a | -$0.19 | $0.25 |
| Operating cash flow | -$2.85M | $3.10M | $8.28M |
| Free cash flow | n/a | $692.0K | $6.41M |
| Cash & equivalents | n/a | $8.45M | n/a |
| Total assets | $29.09M | $187.30M | $70.41M |
| Total liabilities | $26.01M | $99.59M | $47.25M |
| Shareholders' equity | -$2.47M | $87.71M | $23.16M |
| Return on year-end equity | n/a | -13.3% | 62.0% |
| Shares outstanding | 13.70M | 64.46M | 46.66M |
Revenue, most recent five fiscal years
| Fiscal year | Cardiff Lexington Corp | Airsculpt Technologies, Inc. | LifeMD, Inc. |
|---|---|---|---|
| Latest | $11.54M Ended 2025-12-31 | $151.82M Ended 2025-12-31 | $194.06M Ended 2025-12-31 |
| 1 year earlier | $8.27M Ended 2024-12-31 | $180.35M Ended 2024-12-31 | $154.82M Ended 2024-12-31 |
| 2 years earlier | $11.85M Ended 2023-12-31 | $195.92M Ended 2023-12-31 | $152.55M Ended 2023-12-31 |
| 3 years earlier | $10.69M Ended 2022-12-31 | $168.79M Ended 2022-12-31 | $119.03M Ended 2022-12-31 |
| 4 years earlier | $9.88M Ended 2021-12-31 | $133.31M Ended 2021-12-31 | $92.88M Ended 2021-12-31 |